Buchumschlag

Editorial: Low‐Level Viraemia in Chronic Hepatitis B—A Benign State or Missed Opportunity?

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Miriam T. Levy
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
von: Paul Y. Kwo, et al.
Veröffentlicht: (2026)

Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences
von: Bi‐Yu Gao, et al.
Veröffentlicht: (2025)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
von: Jian Wang, et al.
Veröffentlicht: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations
von: Ying‐Nan Tsai, et al.
Veröffentlicht: (2025)

Virological and Immunological Characteristics of HBeAg ‐Positive Chronic Hepatitis B Patients With Low HBsAg Levels
von: Yuxin Chen, et al.
Veröffentlicht: (2024)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations. Authors' Reply
von: Yuxin Chen, et al.
Veröffentlicht: (2025)

Editorial: Chronic Hepatitis B at the Intersection of Immigration, Acculturation and Social Determinants of Health
von: Thomas Hoang, et al.
Veröffentlicht: (2025)

Late Diagnosis of Chronic Hepatitis B in the United States: A Population‐Based, Retrospective Cohort Study From 2007 to 2021
von: Michael H. Le, et al.
Veröffentlicht: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar?
von: Danny Con
Veröffentlicht: (2025)

Editorial: Chronic Hepatitis Delta—We Need More Screening to Improve Knowledge on the Natural History
von: J. Ventre, et al.
Veröffentlicht: (2025)

Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL‐B Study
von: Rui Huang, et al.
Veröffentlicht: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C
von: Shun‐Ichi Wakabayashi, et al.
Veröffentlicht: (2026)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks
von: Chun‐Chieh Chen, et al.
Veröffentlicht: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
von: Lesley A. Patmore, et al.
Veröffentlicht: (2025)

Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study
von: Adriana Palom, et al.
Veröffentlicht: (2026)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
von: Dong Hyun Kim, et al.
Veröffentlicht: (2025)

Letter on “Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China”
von: Ersel Bilgin, et al.
Veröffentlicht: (2025)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
von: Tyng‐Yuan Jang, et al.
Veröffentlicht: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
von: Pei‐Chien Tsai, et al.
Veröffentlicht: (2026)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors
von: Stefan Mauss
Veröffentlicht: (2025)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
von: Rui Huang, et al.
Veröffentlicht: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
von: Ning Yu, et al.
Veröffentlicht: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
von: Yu Jun Wong
Veröffentlicht: (2025)

Letter on “Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign‐Born: The FOCUS‐HBV Multicentre Cohort”
von: Dong Hyun Kim, et al.
Veröffentlicht: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
von: Ying‐Nan Tsai, et al.
Veröffentlicht: (2025)

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure
von: Yanxue Lin, et al.
Veröffentlicht: (2025)

Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study
von: Laurent Lam, et al.
Veröffentlicht: (2024)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
von: Tanat Saeoui, et al.
Veröffentlicht: (2025)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
von: YaoYao Dai, et al.
Veröffentlicht: (2025)

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution
von: Ze‐Hua Zhao, et al.
Veröffentlicht: (2025)

Surviving Hepatitis C—Understanding Death and Survival Beyond Cure
von: Paul J. Clark, et al.
Veröffentlicht: (2025)

Favourable Prognosis of Patients With Untreated HBeAg‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL
von: Jian Wang, et al.
Veröffentlicht: (2024)

CD300A+CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy
von: Peng Zhang, et al.
Veröffentlicht: (2025)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
von: Maria Buti
Veröffentlicht: (2025)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimization
von: Pranab M. Barman
Veröffentlicht: (2026)

Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono‐Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study
von: Raffaella Viganò, et al.
Veröffentlicht: (2025)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass
von: Catherine Jia Lin Tian, et al.
Veröffentlicht: (2024)

Editorial: Addressing Unmet Needs and Socioeconomic Disparity in Patients With Autoimmune Hepatitis
von: Seren Gedallovich, et al.
Veröffentlicht: (2024)

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
von: Grace Lai‐Hung Wong, et al.
Veröffentlicht: (2025)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply
von: Sarah Flatley
Veröffentlicht: (2026)